Dr Paul said there will not be any significant effect if a person gets two different Covid shots, adding that the Centre needed more scrutiny on the matter.
"If second dose of different Covid vaccine is given, any significant adverse effect is unlikely, but we need more scrutiny," Dr Paul said in a media statement on Thursday.
His statement has come after reports emerged that 20 people were given two different coronavirus jabs for their first and second doses in a village in Uttar Pradesh.
They were given a shot of Covishield (AstraZeneca) in early April, but then got the Bharat Biotech's Covaxin as part of their second dose in May.
However, Dr Paul added that the protocol is clear that both doses given should be of the same vaccine. "This matter should be investigated," he said noting the Uttar Pradesh's case.
He further said that India should prepare to give one crore Covid-19 jabs a day which will be possible in a few weeks with due preparation and the vaccination should be taken up to 73 doses in the next three weeks.
Dr Paul, who also heads the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC),told ANI in an interview that the mismatch between the demand and supply of COVID-19 vaccines is universal and the country is ramping up its production of doses.
"We'll have to prepare to give one crore doses in a day. It will be possible in few weeks, we will have to prepare. We made possible 43 lakh doses in a day. We should bring it up to 73 lakh in next three weeks. We should make a system to achieve it," he told ANI.
He said vaccination policy was liberalized on the demand of states.
"States know our vaccine production capacity. When they said they want flexibility and say in vaccine procurement, a new system was brought in under which Centre will procure 50 per cent of vaccines produced domestically for states for free, for 45 group," he said.
"Besides this, a special channel was created for remaining 50 per cent where state governments and private sector can purchase and supply vaccines. On whatever states procure, (from private sector) states have to decide as to which group it has to be given to and taken forward.
"To say that the supply has closed isn't true. Truth is that out of the available production, a distinct part is available to non-govt channels, including state govts, to be used for vaccinating people of their state according to flexible approach by state government," he added.
He said total capacity to produce Covid vaccines across the world is much less than the requirements
"The mismatch between the supply and demand of vaccine is universal. We are in a phase when vaccine supplies are ramping up but they are still not matching the total requirement of the eligible population," he said.
Noting that India is a major hub of vaccine production, he said the government has been working with Covid vaccine companies to increase the production in the country.
Referring to vaccination of children, he said Covaxin has received permission and they will start the paediatric trial.
"I think they are going all the way to two years of age in a systematic way. I have been told that Serum Institute of India wants to begin the paediatric trial of Novavax," he said.
Dr Paul said it has been found out now that Pfizer can be administered to the younger population and one-two countries will start doing it now.
"When any drug/vaccine is discovered, typically it is first sorted out in the adult population because you do not want to risk children....It has been found out now that Pfizer can be administered to the younger population," he said.
"One-two countries will start doing that now. WHO hasn't given any recommendation yet to cover pediatric population in general as any illness in pediatric population is very very mild. If we go with paradigm of deaths as a public health objective," he added. (ANI)
Subscribe to Mint Newsletters
Never miss a story! Stay connected and informed with Mint.
Download
our App Now!!